值得注意的是，美中嘉和此前公告称，中国国家药品监督管理局已于2024年12月6日批准公司设备供应商的质子治疗设备医疗器械注册证的注册申请。美中嘉和公众号12月12日表示，公司旗下广州泰和肿瘤医院质子治疗中心将于2024年12月16日投入运营，正式开机治疗肿瘤患者。Meizhong Jiahe (02453) increased by over 35% during trading, and as of the time of publication, it rose 27.64% to 14.04 Hong Kong dollars, with a transaction amount of 38.1307 million Hong Kong dollars.
According to the Zhitong Finance APP, Meizhong Jiahe (02453) rose over 35% during trading, and as of the time of writing, it is up 27.64%, at 14.04 Hong Kong dollars, with a transaction volume of 38.1307 million Hong Kong dollars.
On the news front, on December 18, 2024, Meizhong Jiahe announced the signing of a financing lease agreement with ZGC TEC LEASING, with a total principal amount not exceeding 0.2 billion yuan for a period of four years, to obtain funds through the sale and leaseback of medical devices. The company believes that entering into this agreement will broaden its financing channels by supplementing operating funds, enhance the sources of liquidity, and optimize its capital structure.
It is noteworthy that Meizhong Jiahe previously announced that the National Medical Products Administration of China approved the registration application for the medical instrument registration certificate of its equipment supplier's proton therapy device on December 6, 2024. Meizhong Jiahe's public account stated on December 12 that the proton therapy center of Guangzhou Taihe Oncology Hospital under the company will commence operation on December 16, 2024, officially starting treatment for cancer patients.
